|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |
|  | **siRNA** | **median** | **min** | **max** | **outlier** | **n** | **p value** |
|  | AllStarNeg (Fig. 6C) | 1.00 | 0.50 | 2.26 | 3.94 | 130 |  |
| AllStarNeg (Fig. S9A) | 1.00 | 0.86 | 1.14 | 1.71 | 20 |  |
| enhanced HPV16 infection | CCNA2\_1 | 3.40 | 0.75 | 9.70 |  | 7 | 0.02 |
| TUBG1\_1 | 2.63 | 0.81 | 9.03 | 10.13 | 23 | 0.0003 |
| TUBG1\_2 | 3.50 | 1.30 | 8.63 |  | 16 | 0.0002 |
| INCENP\_1 | 4.92 | 1.00 | 8.30 |  | 13 | 0.0001 |
| INCENP\_2 | 4.33 | 2.58 | 7.50 |  | 19 | 2x10-9 |
| AURKB\_1 | 7.90 | 3.20 | 9.30 |  | 19 | 2x10-11 |
| AURKB\_2 | 4.08 | 1.58 | 7.90 |  | 19 | 2x10-8 |
| ANAPC1\_1 | 1.44 | 0.69 | 2.90 | 5.00 | 45 | 0.001 |
| ANAPC1\_2 | 2.88 | 1.06 | 6.91 | 6.94 | 35 | 7x10-9 |
| ANAPC5\_1 | 0.83 | 0.50 | 2.91 | 7.13 | 46 | 0.03 |
| ANAPC5\_2 | 2.42 | 1.25 | 9.56 |  | 13 | 0.03 |
| KIF11\_2 | 1.33 | 0.83 | 3.29 | 5.83 | 12 | 0.1 |
| KIF23\_1 | 1.32 | 0.58 | 2.85 | 4.10 | 50 | 0.03 |
| KIF23\_2 | 1.38 | 0.58 | 4.33 | 7.19 | 29 | 0.01 |
| CEP55\_1 | 1.54 | 0.75 | 3.70 |  | 30 | 0.0007 |
| CEP55\_2 | 1.60 | 0.75 | 2.50 |  | 19 | 0.02 |
| PPP2R2A\_1 | 4.14 | 1.29 | 6.14 | 9.14 | 26 | 6x10-7 |
| CENPE\_1 | 4.29 | 2.14 | 9.86 | 11.43 | 20 | 2x10-6 |
| reduced HPV16 infection | HGF\_1 | 1.20 | 0.58 | 3.15 | 3.75 | 57 | 0.07 |
| H2AFZ\_1 | 1.20 | 0.60 | 3.00 | 3.40 | 79 | 0.04 |